Human Health & Nutrition
Solutions for personalized treatment and preventive care
At HORAIZON, we are committed to provide personalized treatment and preventive care through advanced technology. By collaborating with our customers we examine individual microbial profiles, we enhance disease diagnosis and tailor treatments to each person’s unique needs.
The role of Gut Microbiome in Health
The gut microbiome significantly influences digestion, immune function, and overall health. Established in early childhood, it evolves due to diet, medications, and environment. A balanced microbiome benefits health, but disruptions can lead to issues like weight gain, high blood sugar, and high cholesterol, etc. Understanding and maintaining microbiome equilibrium is crucial for preventing these health complications and promoting overall well-being. MicrobeApp provides advanced analysis to help you achieve and sustain this balance.
Microbiome refers to the collective microorganisms residing in various environments, such as the human body. MicrobeApp utilizes advanced technology to analyze these microbial communities and offers personalized recommendations based on the dynamic changes in the microbiome to help you improve your health and reach your full potential.
Microbial diversity, which encompasses both the variety of species in the gut microbiome and their even distribution, is a key indicator of gut health. At HORAIZON, we understand that a high level of microbial diversity, characterized by a wide range of species evenly distributed throughout the gut, signifies a healthy and resilient gut. Our platform is designed to support and enhance this diversity, providing tailored solutions to promote optimal gut health and overall well-being for our clients.
Diet is a key factor in maintaining microbial balance. Our aim is to emphasize the importance of fiber-rich diets, probiotics, and supplements in supporting microbial diversity. Additionally, Fecal Microbial Transplants (FMT) illustrate the significant impact of the microbiome on health. By manipulating the gut microbiome through targeted dietary choices and interventions, MicrobeApp enhances personalized nutrition. Our platform allows for time-based analysis, enabling you to monitor and adjust your gut health as often as needed to achieve optimal results.
Monitoring bowel movements is crucial for digestive health. Changes in stool color, texture, and shape can signal various health issues, from infections to more serious conditions like cancer. A healthy gut microbiome, with more beneficial than harmful bacteria, supports digestion and can influence stool consistency and color. Factors like diet, hydration, and transit time also play a role. With MicrobeApp, you can gain insights into these indicators, facilitating your journey toward improved gut health.
MicrobeApp
MicrobeApp provides advice, services, and support that cover every aspect of gut microbiome health. We focus on end-to-end solutions to address all stages of your microbiome journey, from initial assessment and analysis to personalized intervention and ongoing management. With our comprehensive approach, we aim to surpass traditional methods and introduce a new way in the microbiome field, that is painless, non-invasive, and quick.
From Weeks to Seconds, Redefining Microbiome Analysis
Traditional microbiome analysis is often a time-consuming and costly process, requiring specialized equipment and expert teams. Results can take 2-3 weeks to process, which could delay critical interventions. In contrast, Microbeapp delivers rapid results within seconds using just a digital photo of a small fecal sample, making the process hassle-free, cost-effective, and reliable.
01
Your gut health simplified with advanced technology
Our platform is built from the ground to help people make informed decisions about their health with just one click. Microbeapp combines your microbiome data with nutritional insights to give you a clear picture of your health. We assess key microbial biomarkers, including microbial diversity and the following key groups:
- Butyrate and SCFA Producers
- Fermenters and Fiber Degraders
- Pathogen Inhibitors and Miscellaneous Roles
02
Visual elements like speedometers and gauges highlight which aspects of your gut microbiome are resilient or at risk, while also showing whether your microbial health is improving or declining. Like that, through precise microbiome analysis, we are able to tackle and transform your gut health.
Transformative Gut Health Management
03
Machine Learning to discover Microbial Dynamics and Optimize Nutrition
Our platform integrates various data sources, from diverse human populations, to build and refine state-of-art deep learning models of gut health. By examining microbial interactions and leveraging these comprehensive insights, we develop targeted dietary recommendations that optimize individual health outcomes while addressing specific health concerns. Microbeapp’s innovative use of non-invasive technology ensures that our analyses are both accessible and efficient.
04
Microbeapp is designed with a robust and scalable technology that uses cutting edge and accurate image analysis. Our goal is to accelerate the delivery of superior solutions, enhancing microbial health and wellbeing more efficiently for those who need it.
- Advanced Pipeline: Includes image processing, machine learning algorithms, and data analytics modules.
- High-Quality Insights: Transforms raw data into actionable insights for better health decisions.
- Continuous Data Integration: Incorporates new samples and research findings to refine models and improve results.
Advanced, Robust Technology for Informed Decision-Making
Get started with MicrobeApp
Collect the Sample
Take a small fecal sample for analysis
Capture and Upload Your Sample
Use your smartphone to take a photo and upload it through the app
Receive Insights
Get personalized health insights based on your microbiome within seconds
Our projects & Collaborations
‘GEEF om je buik’: Promoting health with Microbeapp
Using the Microbeapp we aim to provide immediate feedback on how their diet influences their microbiome, guiding them toward healthier choices.
‘GEEF om je buik’: Promoting health
HORAIZON is partnering with Vrije Universiteit Amsterdam (VU Amsterdam) on the 'GEEF om je buik' study. We’re using the Microbeapp platform to analyze participants' gut microbiota. Our aim is to provide immediate feedback on how their diet influences their microbiome, guiding them toward healthier choices.
Analyzing gut microbiota is challenging due to its complexity and the invasive nature of sample collection methods like endoscopies, which can be uncomfortable and carry certain risks. The process requires advanced techniques and specialized equipment, making it both time-consuming and expensive. Furthermore the analysis generates vast and complex datasets that require a team of experts including microbiologists, R&D specialists, and bioinformaticians to accurately interpret using sophisticated bioinformatics tools. The variability of the gut microbiome among individuals, which can change rapidly based on factors like diet and environment, further complicates the analysis, adding another layer of complexity to the process.
However, the 'GEEF om je buik' study, led by Remco Kort, Nicole de Wit, Marieke van de Put, and Maartje van den Belt from Vrije Universiteit Amsterdam and Wageningen University & Research, aims to simplify this process. Given these challenges, HORAIZON is partnering with Vrije Universiteit Amsterdam (VU Amsterdam) on the 'GEEF om je buik' study.
The research project, titled GEEF (Gut Health Enhancement by Eating Favourable foods), is a randomized controlled trial involving 150 healthy adults. Participants will follow two different dietary interventions and receive direct feedback on how these diets affect their gut microbiota. The research will also examine the impact on 92 inflammatory markers, gastrointestinal health, well-being, and sleep.
By incorporating this technology, we could improve preventive care and offer a more cost-effective and accessible way to monitor health.
Epipredict: Tailored Crohn’s Disease Therapy
The Epigenetics Project is a groundbreaking initiative aimed at transforming the treatment of Crohn’s Disease.
Epipredict: Treatment recommendation for Crohn’s disease patients
In collaboration with Amsterdam UMC and the Erasmus MC Incubator, HORAIZON is contributing to the Epigenetics Project, a groundbreaking initiative aimed at transforming the treatment of Crohn’s Disease. This project leverages machine learning and genetic data to enable more personalized drug choices.
EpiPredict is a software tool designed to assist doctors in selecting the most effective treatment for Crohn’s Disease. It analyzes genetic data from patients aged 18 to 80 and predicts how well they might respond to medications such as Vedolizumab and Ustekinumab. By offering personalized treatment recommendations, it helps healthcare professionals make more informed decisions, leading to better patient outcomes and fewer side effects.
Currently, choosing the right medication for Crohn's disease often involves random assignment and lengthy waiting times to assess efficacy through colonoscopy. This process can lead to prolonged suffering if treatments are ineffective. The Epigenetics Project seeks to overcome this by using patient samples from hospitals. Accessible in clinical settings, hospitals, and specialized clinics through secure internet connections, EpiPredict does not directly treat or prevent Crohn's Disease. It plays a crucial role in enhancing treatment precision by developing a model that tailors drug recommendations based on individual epigenetic profiles.
AI Antenna: AI for Heart Disease Regeneration
This collaborative project is focused on developing a regenerative therapy for patients with ischemic heart disease.
AI ANTENNA PROJECT: AI for Heart Disease Regeneration
Our latest collaborative project named AI Antenna , in partnership with SUMMA Biotech, is focused on developing a regenerative therapy for patients with ischemic heart disease.
This innovative therapy seeks to stimulate the regeneration of damaged heart tissues, potentially restoring heart function in patients suffering from heart failure due to ischemia.
As part of the project, we are exploring whether patients who respond well to the current standard of care may possess a higher baseline regenerative capacity. Identifying such patients could make them ideal candidates for regenerative therapies. To achieve this, we will use advanced AI models to analyze a range of data, including demographics, clinical parameters, and RNA sequencing, in order to pinpoint those most likely to benefit from these next-generation treatments.
Our approach focus on identifying sub-populations of patients who are particularly responsive to the standard care. By examining treatment response data alongside clinical and RNA sequencing parameters, we aim to develop a model that differentiates between patients who respond to standard treatments and those who do not. This will allow us to target patients with a potentially higher regenerative capacity who could benefit most from the new regenerative therapies being developed.
As we begin this important collaboration, we look forward to work towards developing targeted therapies that have the potential to improve outcomes for patients with ischemic heart disease.
Sepsis Detection in Neonates: AI-Powered Approach
Our company is collaborating with the University of Amsterdam to address the critical challenge of Late-Onset Neonatal Sepsis (LONS).
Sepsis Detection in Neonates: AI-Powered Approach
Our company is collaborating with the University of Amsterdam to address the critical challenge of late-onset neonatal sepsis (LONS), which affects 10-37% of preterm neonates. Sepsis is a life-threatening condition that arises when the body's response to an infection causes injury to its own tissues and organs.
This condition poses significant risks, particularly due to the immature immune systems of these infants. Current diagnostic methods rely on time-consuming blood tests to detect pathogens, which can delay treatment and impact outcomes. To improve diagnostic efficiency, we are exploring alternative approaches using microbiome data from fecal samples.
Our goal is to leverage AI to accurately differentiate between healthy neonates and those with sepsis based on their microbiome profiles. Using advanced analytical techniques such as logistic regression with stability selection and random forest methods, we analyze microbiome data to identify key indicators of sepsis.
By developing and refining these AI-driven models, we aim to provide a faster and more accurate diagnostic tool that could significantly enhance early detection and improve treatment outcomes for vulnerable preterm infants.
AI Antenna: AI for Heart Disease Regeneration
This collaborative project is focused on developing a regenerative therapy for patients with ischemic heart disease. In partnership with SUMMA Biotech.
AI ANTENNA PROJECT: AI for Heart Disease Regeneration
Our latest collaborative project named AI Antenna , in partnership with SUMMA Biotech, is focused on developing a regenerative therapy for patients with ischemic heart disease.
This innovative therapy seeks to stimulate the regeneration of damaged heart tissues, potentially restoring heart function in patients suffering from heart failure due to ischemia.
As part of the project, we are exploring whether patients who respond well to the current standard of care may possess a higher baseline regenerative capacity. Identifying such patients could make them ideal candidates for regenerative therapies. To achieve this, we will use advanced AI models to analyze a range of data, including demographics, clinical parameters, and RNA sequencing, in order to pinpoint those most likely to benefit from these next-generation treatments.
Our approach focus on identifying sub-populations of patients who are particularly responsive to the standard care. By examining treatment response data alongside clinical and RNA sequencing parameters, we aim to develop a model that differentiates between patients who respond to standard treatments and those who do not. This will allow us to target patients with a potentially higher regenerative capacity who could benefit most from the new regenerative therapies being developed.
As we begin this important collaboration, we look forward to work towards developing targeted therapies that have the potential to improve outcomes for patients with ischemic heart disease.
Sepsis Detection in Neonates: AI-Powered Approach
Our company is collaborating with the University of Amsterdam to address the critical challenge of Late-Onset Neonatal Sepsis (LONS).
Sepsis Detection in Neonates: AI-Powered Approach
Our company is collaborating with the University of Amsterdam to address the critical challenge of late-onset neonatal sepsis (LONS), which affects 10-37% of preterm neonates. Sepsis is a life-threatening condition that arises when the body's response to an infection causes injury to its own tissues and organs.
This condition poses significant risks, particularly due to the immature immune systems of these infants. Current diagnostic methods rely on time-consuming blood tests to detect pathogens, which can delay treatment and impact outcomes. To improve diagnostic efficiency, we are exploring alternative approaches using microbiome data from fecal samples.
Our goal is to leverage AI to accurately differentiate between healthy neonates and those with sepsis based on their microbiome profiles. Using advanced analytical techniques such as logistic regression with stability selection and random forest methods, we analyze microbiome data to identify key indicators of sepsis.
By developing and refining these AI-driven models, we aim to provide a faster and more accurate diagnostic tool that could significantly enhance early detection and improve treatment outcomes for vulnerable preterm infants.
AIBiomics and Horaizon are joining forces
Understanding your microbial health should be simple and clear. We make this possible by turning your microbiome data into a digital format through our platform, available on both mobile and web.
AIBIOMICs and HORAIZON are joining forces
Understanding your microbial health should be simple and clear. We make this possible by turning your microbiome data into a digital format through our platform, available on both mobile and web. With AIBiomics and HORAIZON working together, we offer an easy and non-invasive way to monitor and assess your gut health, giving you insights into whether your diet supports a balanced microbiome.
AIBiomics has created an advanced and rapid gut microbiota analysis tool that can be used to manage diabetes, pediatric ailments, colorectal cancer, and chronic bowel disorders. By utilizing this technology, we aim to provide precise, fast, and accessible health diagnostics, tailored to individual needs
More precisely it can assist individuals, particularly those with gastrointestinal disorders, in managing their microbial health and enhancing their overall well-being, through personalized insights, such as dietary adjustments. The results can be easily obtained by simply uploading a photo to the AIBiomics app. This technology has been tested on thousands of samples, showing its reliability for checking health and identifying biomarkers that are related to an imbalanced microbiome.
AIBiomics is working with HORAIZON BV and the Microbiome Sequence Facility at Amsterdam UMC to improve the MicrobeLink app. The technology behind this platform, patented by HORAIZON BV, uses advanced machine learning and image analysis to identify patterns from a small fecal sample placed on white paper and photographed with a smartphone. UvA Ventures Holding supports this project by investing in innovative research from the University of Amsterdam, helping to bring these advanced solutions to the market effectively.
Visit https://www.aibiomics.com/ for more information.